We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dyadic Granted Patent for High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dyadic Granted Patent for High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Dyadic International, Inc. has announced that it was granted U.S. patent 7,122,330, "High-Throughput Screening of Expressed DNA Libraries in Filamentous Fungi," by the U.S. Patent and Trademark Office.

Dr. Glenn Nedwin, Dyadic's Chief Scientific Officer, Executive Vice President and President of Dyadic's Biosciences Business, said, "This patent protects Dyadic's novel technology for robotic screening in filamentous fungi using our proprietary C1 Host Technology platform."

"With broad claims covering a number of other industrially relevant fungi, including Trichoderma and Aspergillus, we believe the patent also validates Dyadic's 'one stop shop' model where gene discovery and improvement, gene expression, and product manufacturing in quantities from 1 ml to 150,000 liters can all be performed in the same host organism."

"We believe that this, in turn, should improve the odds of identifying potentially useful proteins, shorten R&D development timelines, and reduce development costs."

Dr. Nedwin added, "We already are using this patented technology in Dyadic's programs to identify optimal enzymes and enzyme mixtures to increase the efficiency of extracting sugars from renewable biomass, a critical step in the production of low-cost cellulosic ethanol, plastics, polymers and other products now derived from petroleum."

"We also are using our technology to expand the pipeline of new, more effective and lower cost enzymes used in the pulp & paper, textile, animal feed and other industrial processes, and are developing the technology to facilitate the rapid, low-cost screening of antibodies and other proteins for therapeutic applications."

"We believe that the unique capabilities of our patented technology give us an important advantage in the development of cost-effective commercial products in each of our target markets."